Back to top

Press Releases

Zacks Equity Research

The Zacks Analyst Blog Highlights: Alphabet, Novo Nordisk, Enterprise Products Partners, Textron and Xerox


Trades from $3

For Immediate Release

Chicago, IL – October 11, 2016 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Alphabet (NASDAQ:(GOOGL - Analyst Report) -Free Report), Novo Nordisk (NYSE:(NVO - Analyst Report) -Free Report), Enterprise Products Partners (NYSE:(EPD - Analyst Report) -Free Report), Textron (NYSE:(TXT - Analyst Report) -Free Report) and Xerox (NYSE:(XRX - Analyst Report) -Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Monday’s Analyst Blog:

Top Research Reports for Alphabet, Novo Nordisk and Enterprise Products

Today's Research Daily features new research reports on 16 major stocks, including Alphabet ((NASDAQ:(GOOGL - Analyst Report) -Free Report), Novo Nordisk (NYSE:(NVO - Analyst Report) -Free Report) and Enterprise Products Partners (NYSE:(EPD - Analyst Report) -Free Report).

Google parent Alphabet shares lagged the broader market and the Tech sector this year, but the company remains well positioned for outperformance in the long run given its focus on innovation, strategic acquisitions, the Android OS and a number of other diversification moves. In its Oct 4 event, the tech giant unveiled a range of new products including two smartphones, a 5.0 inch Pixel and a 5.5 inch Pixel XL, and an Android virtual reality headset, Daydream. However, growing competition and legal hassles remained as major headwinds. (You can read the full research report on Alphabet here>>)

Novo Nordisk shares have been laggards this year, as the Danish pharmaceutical giant has been grappling with a number of a company-specific issues on top of the unfavorable political/regulatory backdrop for the space as a whole. The company's strong presence in the Diabetes Care market and focus on therapeutic proteins within insulin is a big positive. To that end, Victoza remains a key growth area for the company. But a slew of patent expirations, growing pricing pressures for a number of its drugs and the recent decision to discontinue the development of liraglutide as a joint therapy to insulin in type I diabetes remain headwinds. The Zacks analyst discusses the pros & cons of investing in Novo Nordisk shares at this stage. (You can read the full research report on Novo Nordisk here>>)

Enterprise Products Partners shares have performed in line with the broader market this year, but lagged the energy space as a whole on NGL pricing issues and the recent uptrend in long-term interest rates. These issues notwithstanding, the Zacks analyst likes the partnership's large scale and diverse midstream asset base and multi-billion dollar projects under construction, which are likely to support meaningful distribution growth. (You can read the full research report on Enterprise Products Partners here>> )

Other noteworthy reports we are featuring today include Textron (NYSE:(TXT - Analyst Report) -Free Report) and Xerox (NYSE:(XRX - Analyst Report) -Free Report).

Free Access: All Zacks Research Reports

Starting today, you are invited to download in-depth analysis reports covering more than 1,000 of the most widely followed stocks. Valued at $25 each, they are yours to consult over the next 30 days absolutely free. They feature sensitive Zacks Rank information on each stock that you won't find anywhere else. See the reports free >>

You can find all of today's stock research reports here>>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on GOOGL - FREE

Get the full Report on NVO - FREE

Get the full Report on EPD - FREE

Get the full Report on TXT - FREE

Get the full Report on XRX - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.